Navigation Links
Genzyme Receives Approval to Market Elaprase(R) in Japan
Date:10/4/2007

CAMBRIDGE, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that it has received approval to market Elaprase(R) (idursulfase) in Japan for the treatment of Hunter syndrome. Elaprase is an enzyme replacement therapy developed by Shire Human Genetic Therapies Inc., and Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with Shire. Genzyme intends to launch Elaprase this quarter, following reimbursement approval.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare, life-threatening genetic condition mainly affecting males that results from the absence or insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. Without this enzyme, cellular waste products accumulate in tissues and organs which then begin to malfunction, leading to severe clinical complications and early mortality.

Elaprase is the fifth enzyme replacement therapy that Genzyme has introduced in Japan. The company also markets Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; Aldurazyme(R) (laronidase) for MPS I; and Myozyme(R) (alglucosidase alfa) for Pompe disease.

"Our deep experience in Japan in the area of lysosomal storage disorders will enable us to make Elaprase available to all patients who need treatment as quickly as possible," said David Meeker, M.D., president of Genzyme's Lysosomal Storage Disorders business unit. "We anticipate that Elaprase will become an increasingly significant contributor for us as we introduce the product across the region."

Genzyme is currently working to obtain marketing approval for Elaprase in several addition
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Medical College receives $377K to study brain disease
5. Lucigen receives $750K grant to boost biofuel yields
6. Medical College receives $1.4M cancer grant
7. Wisconsin biotech firm receives $107K NIH grant
8. InvivoSciences receives NIH grant for heart technology
9. Medical College receives $11 million grant to study high blood pressure
10. Madison business receives $115,000 of new state biofuels funding
11. Superior receives funds for technical training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... Inc. (Nasdaq: ANDS ) announced today that it ... conference on Thursday, April 2, 2009 at 2:00 p.m. EDT ... the Millennium Broadway Hotel in New York City. Steve ... provide an overview of Anadys and its clinical programs: ANA598 ...
... March 26 NATURAL FUELS INDUSTRIES, INC. (Pink ... raised their rating for the Company to "Fully Compliant", ... categorizes all securities trading over-the-counter into easily identifiable tiers ... public information available in a timely manner. Subsequent ...
... R&D Directions honors Dr. Sellers, pioneering work in human ... KNDL ), a leading, global full-service clinical research ... and General Manager of the company,s Early Stage Unit ... People in R&D" by leading industry publication R&D ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 2Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D' 3
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... The Nature Conservancy and Conservation International (CI) have ... Rica in one of the largest debt-for-nature swaps in ... Costa Ricas most critically threatened tropical forests, with the ... and Costa Rica spending that amount on tropical forest ...
... in the expression of genes may be the reason why ... quickly develop a tolerance, biologists at The University of Texas ... graduate student Yan Wang, used the fruit fly Drosophila melanogaster ... becomes tolerant to sedation with organic solvent inhalants. The ...
... Frankel, a scientific imagist and researcher at Harvard ... the recipient of the 2007 Lennart Nilsson Award. ... exquisite works of art and crystal-clear scientific illustrations ... public and scientific community alike. The Lennart ...
Cached Biology News:Costa Rica, US announce historic debt-for-nature swap 2Costa Rica, US announce historic debt-for-nature swap 3Tolerance to inhalants may be caused by changes in gene expression 2Lennart Nilsson Award 2007 2
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... UN-SCAN-IT gel Software converts any scanner into ... numerous options and features, the basic operation ... JPEG, PCX, BMP, etc.) into pixel density ... steps. Turn your scanner ...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... tubes and 96 well plates. microCLEAN is an ... a half spin DNA cleanup reagent. It can ... type of double stranded DNA, efficiently removing reaction ... or unlabelled). It is therefore ideally suited to ...
Biology Products: